METASTRON Side Effects

6204943-8 | Anaemia, Anorexia, Dementia, Hallucination, Hydronephrosis, Hypoalbuminaemia, Nephrostomy, Oedema, Pruritus
on May 13, 2009 Male patient from JAPAN , 66 years of age, weighting 138.9 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, anorexia, dementia (What is dementia?), hallucination, hydronephrosis, hypoalbuminaemia, nephrostomy, oedema, pruritus. Metastron dosage: Single Dose, I.v.. Patient was hospitalized.

6204942-6 | Anorexia, Condition Aggravated, Constipation, Diarrhoea, Gastritis, Headache, Oesophageal Candidiasis, Otitis Media Chronic, Pain
Patient was taking Metastron (View Usage). Patient had the following side effects: anorexia, condition aggravated, constipation (What is constipation?), diarrhoea, gastritis, headache (What is headache?), oesophageal candidiasis, otitis media chronic, pain (What is pain?) on May 13, 2009 from JAPAN Additional patient health information: Male patient , 77 years of age, weighting 154.3 lb, was diagnosed with metastatic pain and. Metastron dosage: 140 Mbq, Single Dose, I.v. ; Single Dose. Patient was hospitalized.

6202897-1 | Diarrhoea, Sepsis
Adverse event was reported on May 11, 2009 by a Male patient taking Metastron (View Usage) (Dosage: 110 Mbq, Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , 59 years of age, After Metastron was administered, patient had the following side effects: diarrhoea, sepsis (What is sepsis?).

6169792-8 | Anaemia, Condition Aggravated, Feeling Hot, Humerus Fracture, Joint Hyperextension, Metastatic Pain, Pathological Fracture, Platelet Count Decreased, Vomiting
on Apr 14, 2009 Female patient from JAPAN , 44 years of age, weighting 110.2 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, condition aggravated, feeling hot, humerus fracture, joint hyperextension, metastatic pain, pathological fracture, platelet count decreased, vomiting. Metastron dosage: 3.2 Ml, Single Dose, I.v.. Patient was hospitalized and became disabled.


6148466-3 | Anaemia, Depressed Level Of Consciousness, Disseminated Intravascular Coagulation, Platelet Count Decreased
on Feb 19, 2009 Female patient from JAPAN , 57 years of age, weighting 134.5 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: anaemia, depressed level of consciousness, disseminated intravascular coagulation, platelet count decreased. Metastron dosage: 123 Mbq, Single Dose, I.v.. During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

6147011-6 | Anaemia, Disease Progression, Pain, Prostate Cancer Metastatic
Patient was taking Metastron (View Usage). After Metastron was administered, patient had the following side effects: anaemia, disease progression, pain (What is pain?), prostate cancer metastatic on Mar 23, 2009 from JAPAN Additional patient health information: Male patient , 26 years of age, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v..

6140119-0 | Gait Disturbance, Monoplegia, Rectal Ulcer Haemorrhage
Adverse event was reported on Mar 17, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , 67 years of age, weighting 127.9 lb, Patient experienced the following unwanted or unexpected effects: gait disturbance, monoplegia, rectal ulcer haemorrhage. During the same period patient was treated with DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ). Patient was hospitalized and became disabled.

6140118-9 | Condition Aggravated, Diarrhoea, Pneumonia
on Mar 18, 2009 Male patient from JAPAN , 78 years of age, weighting 105.8 lb, was diagnosed with metastases to bone and was treated with Metastron (View Usage). Patient had the following side effects: condition aggravated, diarrhoea, pneumonia (What is pneumonia?). Metastron dosage: Single Dose, I.v..

6137531-2 | Anorexia, Asthenia, Diarrhoea
on Mar 17, 2009 Male patient from JAPAN , 79 years of age, was diagnosed with metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: anorexia, asthenia, diarrhoea. Metastron dosage: Single Dose, I.v.. Patient was hospitalized.

6132602-9 | No Therapeutic Response, Sepsis, White Blood Cell Count Decreased
Patient was taking Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: no therapeutic response, sepsis (What is sepsis?), white blood cell count decreased on Mar 13, 2009 from JAPAN Additional patient health information: Male patient , 55 years of age, weighting 198.4 lb, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v..

6120909-0 | Dementia
Adverse event was reported on Feb 20, 2009 by a Female patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , 66 years of age, weighting 116.8 lb, Patient had the following side effects: dementia (What is dementia?). During the same period patient was treated with FENTANYL (DUROTEP) (View Fentanyl (durotep) Review and Fentanyl (durotep) Label ), MORPHINE HYDROCHLORIDE (OPSO) (View Morphine Hydrochloride (opso) Review and Morphine Hydrochloride (opso) Label ). Patient was hospitalized.

6115898-9 | Altered State Of Consciousness, Delirium, Hypercalcaemia, Pain
on Feb 24, 2009 Male patient from JAPAN , 67 years of age, weighting 130.1 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: altered state of consciousness, delirium, hypercalcaemia, pain (What is pain?). Metastron dosage: 3.1 Ml, Single Dose, I.v.. Patient was hospitalized.

6073310-2 | Malaise, Nausea
on Jan 28, 2009 Female patient from JAPAN , 45 years of age, weighting 96.78 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: malaise, nausea (What is nausea?). Metastron dosage: 81.8 Mbq, Single Dose, 1.v.. Patient was hospitalized.

6066094-5 | Disease Progression
Patient was taking Metastron (View Usage). Patient had the following side effects: disease progression on Jan 22, 2009 from JAPAN Additional patient health information: Female patient , 70 years of age, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v..

6066078-7 | Anaemia, Delirium
Adverse event was reported on Jan 09, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose) was diagnosed with metastatic pain and. Location: JAPAN , 77 years of age, weighting 98.99 lb, After Metastron was administered, patient had the following side effects: anaemia, delirium. During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ). Patient was hospitalized.

6065532-1 | Bone Pain, Hot Flush, Hypoaesthesia, Malignant Neoplasm Progression, Metastases To Bone, Nausea, Pyrexia
on Jan 22, 2009 Female patient from JAPAN , 58 years of age, weighting 77.82 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: bone pain, hot flush, hypoaesthesia, malignant neoplasm progression, metastases to bone, nausea (What is nausea?), pyrexia. Metastron dosage: I.v.. During the same period patient was treated with PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ).

6065531-X | Anaemia, Headache, Platelet Count Decreased, Subdural Haemorrhage
on Jan 22, 2009 Male patient from JAPAN , 66 years of age, weighting 112.7 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: anaemia, headache (What is headache?), platelet count decreased, subdural haemorrhage. Metastron dosage: Single Dose, I.v.. Patient was hospitalized.

6065529-1 | No Adverse Event
Patient was taking Metastron (View Usage). After Metastron was administered, patient had the following side effects: no adverse event on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 87 years of age, was diagnosed with metastatic pain and. Metastron dosage: 2.8 Ml, Single Dose, I.v..

6063744-4 | Bone Marrow Failure, Hepatic Function Abnormal, Metastases To Liver, Metastases To Peritoneum
Adverse event was reported on Jan 22, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , 71 years of age, weighting 116.8 lb, Patient experienced the following unwanted or unexpected effects: bone marrow failure, hepatic function abnormal, metastases to liver, metastases to peritoneum.

6063132-0 | Disease Progression, No Adverse Event
on Jan 22, 2009 Female patient from JAPAN , 72 years of age, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: disease progression, no adverse event. Metastron dosage: 82 Mbq, Single Dose, I.v..

6063119-8 | Disease Progression
on Jan 22, 2009 Female patient from JAPAN , 73 years of age, was diagnosed with metastases to bone and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: disease progression. Metastron dosage: Single Dose, I.v..

6063116-2 | Disease Progression, Platelet Count Decreased
Patient was taking Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, platelet count decreased on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 41 years of age, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v.. During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ).

6062499-7 | Asthenia, Pain
Adverse event was reported on Jan 22, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastases to bone, metastatic pain and. Location: JAPAN , 76 years of age, weighting 95.46 lb, Patient had the following side effects: asthenia, pain (What is pain?). During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ), LOXOPROFEN (View Loxoprofen Review and Loxoprofen Label ), MORPHINE (View Morphine Review and Morphine Label ), FLURBIPROFEN AXETIL (View Flurbiprofen Axetil Review and Flurbiprofen Axetil Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), NAPROXEN (View Naproxen Review and Naproxen Label ).

6062491-2 | Disease Progression
on Jan 22, 2009 Male patient from JAPAN , weighting 92.59 lb, was diagnosed with metastases to bone, metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: disease progression. Metastron dosage: Single Dose, I.v.. During the same period patient was treated with OXYCODONE HYDROCHLORIDE (View Oxycodone Hydrochloride Review and Oxycodone Hydrochloride Label ), LOXOPROFEN SODIUM (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ).

6062488-2 | Bone Marrow Failure, Disease Progression
on Jan 22, 2009 Female patient from JAPAN , 67 years of age, weighting 83.56 lb, was diagnosed with metastases to bone, metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, disease progression. Metastron dosage: Single Dose, I.v..

6062486-9 | Disease Progression
Patient was taking Metastron (View Usage). Patient had the following side effects: disease progression on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 48 years of age, weighting 127.9 lb, was diagnosed with metastases to bone, metastatic pain and. Metastron dosage: Single Dose, I.v.. During the same period patient was treated with OXYCODONE HYDROCHLORIDE (View Oxycodone Hydrochloride Review and Oxycodone Hydrochloride Label ).

6062480-8 | Disease Progression, No Adverse Event
Adverse event was reported on Jan 22, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastases to bone, metastatic pain and. Location: JAPAN , 67 years of age, weighting 131.4 lb, After Metastron was administered, patient had the following side effects: disease progression, no adverse event. During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ), ALENDRONATE SODIUM (View Alendronate Sodium Review and Alendronate Sodium Label ).

6062477-8 | Condition Aggravated, Hepatic Function Abnormal
on Jan 22, 2009 Male patient from JAPAN , weighting 97.00 lb, was diagnosed with metastases to bone, metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, hepatic function abnormal. Metastron dosage: Single Dose, I.v.. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), TXT (View Txt Review and Txt Label ).

6062474-2 | Cerebral Infarction, Disease Progression
on Jan 22, 2009 Female patient from JAPAN , 45 years of age, was diagnosed with metastases to bone, metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: cerebral infarction, disease progression. Metastron dosage: 70 Mbq, Single Dose, I.v..

6062378-5 | Condition Aggravated, Malignant Pleural Effusion
Patient was taking Metastron (View Usage). After Metastron was administered, patient had the following side effects: condition aggravated, malignant pleural effusion on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 57 years of age, weighting 106.9 lb, was diagnosed with metastases to bone, metastatic pain and. Metastron dosage: Nr, Single Dose, I.v..

6062376-1 | Disease Progression
Adverse event was reported on Jan 22, 2009 by a Male patient taking Metastron (View Usage) (Dosage: 3.1 Ml, Single Dose, I.v.) was diagnosed with metastases to bone, metastatic pain and. Location: JAPAN , 59 years of age, weighting 132.3 lb, Patient experienced the following unwanted or unexpected effects: disease progression. During the same period patient was treated with GOSERELIN ACETATE (View Goserelin Acetate Review and Goserelin Acetate Label ).

6062373-6 | Anaemia, Disease Progression, Haematuria, Tumour Haemorrhage
on Jan 22, 2009 Male patient from JAPAN , weighting 102.1 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: anaemia, disease progression, haematuria, tumour haemorrhage. Metastron dosage: Nr, Single Dose, I.v..

6062370-0 | Emphysema, Malignant Neoplasm Progression, Platelet Count Decreased, Protein Total Decreased, Pulmonary Oedema
on Jan 22, 2009 Male patient from JAPAN , 85 years of age, weighting 90.39 lb, was diagnosed with metastases to bone, metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: emphysema, malignant neoplasm progression, platelet count decreased, protein total decreased, pulmonary oedema. Metastron dosage: 82 Mgq, Single Dose, I.v.. During the same period patient was treated with ZOMETA (View Zometa Review and Zometa Label ), LOXOPROFEN SODIUM (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), HYDROCHLORIDE (View Hydrochloride Review and Hydrochloride Label ), GOSERELIN ACETATE (View Goserelin Acetate Review and Goserelin Acetate Label ).

6062365-7 | Abdominal Pain Upper, Anaemia, Blood Pressure Decreased, Disease Progression, Heart Rate Increased, Intestinal Obstruction, Vomiting
Patient was taking Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, anaemia, blood pressure decreased, disease progression, heart rate increased, intestinal obstruction, vomiting on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 77 years of age, weighting 118.6 lb, was diagnosed with metastatic pain and. Metastron dosage: Nr, Single Dose, I.v.. During the same period patient was treated with PAMIDRONATE DISODIUM (View Pamidronate Disodium Review and Pamidronate Disodium Label ), ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ).

6062363-3 | Disease Progression, Haemoglobin Decreased, Red Blood Cell Count Decreased, Respiratory Failure
Adverse event was reported on Jan 22, 2009 by a Female patient taking Metastron (View Usage) (Dosage: Nr, Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , 49 years of age, weighting 191.8 lb, Patient had the following side effects: disease progression, haemoglobin decreased, red blood cell count decreased, respiratory failure. During the same period patient was treated with ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ).

6062360-8 | Concomitant Disease Aggravated, Disseminated Intravascular Coagulation, Platelet Count Decreased, Pneumonia Aspiration, Sepsis
on Jan 22, 2009 Male patient from JAPAN , weighting 127.9 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: concomitant disease aggravated, disseminated intravascular coagulation, platelet count decreased, pneumonia aspiration, sepsis (What is sepsis?). Metastron dosage: 116 Mbq, Single Dose, I.v..

6062356-6 | Condition Aggravated, Malignant Pleural Effusion, Platelet Count Decreased, Pneumonia
on Jan 22, 2009 Male patient from JAPAN , 60 years of age, weighting 167.6 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, malignant pleural effusion, platelet count decreased, pneumonia (What is pneumonia?). Metastron dosage: 141 Mbq, Single Dose, I.v..

6062336-0 | Disease Progression, No Adverse Event
Patient was taking Metastron (View Usage). Patient had the following side effects: disease progression, no adverse event on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , weighting 1160 lb, . Metastron dosage: Nr, Single Dose, I.v..

6062335-9 | Anorectal Disorder, Bladder Disorder, Disease Progression, Hemiparesis, Respiratory Failure
Adverse event was reported on Jan 22, 2009 by a Female patient taking Metastron (View Usage) (Dosage: Nr, Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , weighting 105.8 lb, After Metastron was administered, patient had the following side effects: anorectal disorder, bladder disorder, disease progression, hemiparesis, respiratory failure.

6062315-3 | Bone Marrow Failure, Delirium, Disease Progression, Pyrexia
on Jan 22, 2009 Male patient from JAPAN , 79 years of age, weighting 81.57 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, delirium, disease progression, pyrexia. Metastron dosage: Nr, Single Dose, I.v..

6062314-1 | Bone Marrow Failure, Disease Progression
on Jan 22, 2009 Male patient from JAPAN , 73 years of age, weighting 132.3 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: bone marrow failure, disease progression. Metastron dosage: Nr, Single Dose, I.v.. During the same period patient was treated with TEGAFUR URACIL (UFT/LV) (View Tegafur Uracil (uft/lv) Review and Tegafur Uracil (uft/lv) Label ), LEUCOVORIN (LV) (View Leucovorin (lv) Review and Leucovorin (lv) Label ), IRINOTECAN (CPP 11) (View Irinotecan (cpp-11) Review and Irinotecan (cpp-11) Label ).

6062305-0 | Bone Marrow Failure, Disease Progression
Patient was taking Metastron (View Usage). After Metastron was administered, patient had the following side effects: bone marrow failure, disease progression on Jan 22, 2009 from JAPAN Additional patient health information: Female patient , 56 years of age, weighting 94.80 lb, was diagnosed with metastatic pain and. Metastron dosage: Nr, Single Dose, I.v..

6062304-9 | Anaemia, Blood Albumin Decreased, Disseminated Intravascular Coagulation, Intra-abdominal Haemorrhage, Oedema, Pleural Effusion, Protein Total Decreased, Somnolence
Adverse event was reported on Jan 22, 2009 by a Female patient taking Metastron (View Usage) (Dosage: Nr, Single Dose) was diagnosed with metastatic pain and. Location: JAPAN , 69 years of age, weighting 98.33 lb, Patient experienced the following unwanted or unexpected effects: anaemia, blood albumin decreased, disseminated intravascular coagulation, intra-abdominal haemorrhage, oedema, pleural effusion, protein total decreased, somnolence. During the same period patient was treated with FENTANYL 75 (View Fentanyl-75 Review and Fentanyl-75 Label ), CLOMIPRAMINE HYDROCHLORIDE (View Clomipramine Hydrochloride Review and Clomipramine Hydrochloride Label ).

6060433-7 | Disease Progression, No Adverse Event
on Jan 22, 2009 Male patient from JAPAN , 44 years of age, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient had the following side effects: disease progression, no adverse event. Metastron dosage: Single Dose.

6060432-5 | Malignant Neoplasm Progression, No Adverse Event, Prostate Cancer Metastatic
on Jan 22, 2009 Male patient from JAPAN , weighting 123.0 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: malignant neoplasm progression, no adverse event, prostate cancer metastatic. Metastron dosage: Single Dose, I.v..

6060431-3 | Disease Progression
Patient was taking Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression on Jan 22, 2009 from JAPAN Additional patient health information: Male patient , 64 years of age, weighting 171.5 lb, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v..

6060430-1 | Lung Cancer Metastatic, Malignant Neoplasm Progression, No Adverse Event
Adverse event was reported on Jan 22, 2009 by a Male patient taking Metastron (View Usage) (Dosage: Single Dose, I.v.) was diagnosed with metastatic pain and. Location: JAPAN , weighting 174.2 lb, Patient had the following side effects: lung cancer metastatic, malignant neoplasm progression, no adverse event.

6060429-5 | Disease Progression, No Adverse Event
on Jan 22, 2009 Male patient from JAPAN , 66 years of age, was diagnosed with metastatic pain and was treated with Metastron (View Usage). After Metastron was administered, patient had the following side effects: disease progression, no adverse event. Metastron dosage: Single Dose, I.v..

6060428-3 | Disease Progression, White Blood Cell Count Decreased
on Jan 22, 2009 Male patient from JAPAN , 67 years of age, weighting 167.6 lb, was diagnosed with metastatic pain and was treated with Metastron (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, white blood cell count decreased. Metastron dosage: Single Dose, I.v..

6060427-1 | Disease Progression, No Adverse Event
Patient was taking Metastron (View Usage). Patient had the following side effects: disease progression, no adverse event on Jan 22, 2009 from JAPAN Additional patient health information: Female patient , 59 years of age, weighting 88.18 lb, was diagnosed with metastatic pain and. Metastron dosage: Single Dose, I.v..